TerminatedNot Applicable

Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine Care

Stopped: Inability to conduct the study

France3 participantsStarted 2020-09-29

Plain-language summary

The aim of this study is looking at the Kinetics of bone turnover markers (C-terminal telopeptides of type I collagene (CTX), amino-terminal telopeptide of type 1 collagen (NTX), Dickkopf-1 (DKK-1) and Sclerostin (SOST)) in serum and urine until 12 months in Patients with Multiple Myeloma Treated With intravenous bisphosphonates in routine care.

Who can participate

Age range65 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patient aged 65 to 75 years of age
✓. Patient with symptomatic multiple myeloma as defined by the criteria of the IMWG
✓. Need to introduced an antiresorptive bone treatment by intravenous bisphosphonate with bone imaging mapping (PET-scanner preferentially) in routine care
✓. Ability and willingness to follow scheduled visits with requested biological samples

What they're measuring

Changes in bone turnover markers

Timeframe: Baseline, then every 2 months in 12 months

Trial details

NCT IDNCT04111809

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-10-20

View on ClinicalTrials.gov More Multiple Myeloma trials